Medicine
Atacand HCT 32 mg/12.5 mg tablet
Atacand HCT 32 mg/12.5 mg tablet is a prescription medicine containing Candesartan cilexetil and Hydrochlorothiazide for oral use, marketed by ANI Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), excursions permitted at 15° to 30°C (59°…
Key facts
- Active ingredient (INN)
- Candesartan cilexetil and Hydrochlorothiazide
- Brand
- Atacand HCT
- Strength
- 32 mg/12.5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 90 tablets
- Marketing authorisation holder
- ANI Pharmaceuticals
- Manufacturer
- ANI Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), excursions permitted at 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 October 2018
- Identifiers
- RxCUI 578325, 578330, 802749 +3DailyMed set ID d91152c4-66ba-466f-b4f9-0da628d42b1dNDC 62559-651Application NDA021093
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 90 tablet in 1 bottle | 62559-651-90 | ANI Pharmaceuticals | 1 October 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 September 2000 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Candesartan cilexetil and Hydrochlorothiazide 32 mg/12.5 mg tablet.
Other strengths and forms of Candesartan cilexetil and Hydrochlorothiazide
Clinical summary
Candesartan cilexetil and Hydrochlorothiazide is a fixed-dose combination of an angiotensin 2 receptor blocker and a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. MedsAcross supplies Candesartan cilexetil and Hydrochlorothiazide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Candesartan cilexetil and HydrochlorothiazideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Candesartan Cilexetil and Hydrochlorothiazide prescribing information (ANI Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Atacand HCT 32 mg/12.5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.